Advanced searches left 3/3

Carboplatin Non-small Cell - Crossref

Summarized by Plex Scholar
Last Updated: 03 May 2022

* If you want to update the article please login/register

Pirfenidone Sensitizes NCI-H460 Non-Small Cell Lung Cancer Cells to Paclitaxel and to a Combination of Paclitaxel with Carboplatin

Our research tested whether pirfenidone sensitizes non-small cell lung cancer cell lung cancer cell lines to chemotherapeutic drugs. Using the sulforhodamine B assay, the cytotoxic effect of paclitaxel in combination with pirfenidone was evaluated on three NSCLC cell lines. Lastly, the ability of pirfenidone to sensitize NCI-H460 cells to a mixture of paclitaxel and carboplatin was explored. Cell growth, viability, and proliferation were reduced by paclitaxel therapy, decreasing cell growth, viability, and proliferation, which lead to cell proliferation change and cell death increase. Importantly, pirfenidone converted NCI-H460 cells to paclitaxel plus carboplatin, which was also accompanied by pirfenidone.

Source link: https://doi.org/10.3390/ijms23073631


A PROSPECTIVE COMPARATIVE STUDY BETWEEN CONCURRENT CHEMO RADIOTHERAPY WITH CISPLATIN AND ETOPOSIDE VERSUS PACLITAXEL AND CARBOPLATIN IN LOCALLY ADVANCED NON SMALL CELL LUNG CARCINOMA

Introduction-The new standard of care for unresectable locally advanced Non-small cell lung cancer is radiation, with concurrent platinum-based doublet chemotherapy. Materials and Methods: Patients of two groups were randomly assigned to External beam radiotherapy in conventional fractionation, as well as concurrent weekly chemotherapy with Inj. paclitaxel and Inj. With overlapping Inj. cisplatin Day 1,8,29,36,36, and Inj. Etoposide Day 1-5 and Day 29-33, both the carboplatin and control group received the same radiotherapy dose with concurrent Inj. complatin Day 1,8,29,36,36, and Inj. Etoposide Day 1-5 and Inj. Patients were initially tested for acute toxicity during radiation therapy and then every three months for at least six months, then every three months for at least six months. Conclusions- Overall treatment response in the Study Arm was higher than the control arm, according to the study arm. In both the arms of the study, acute lung, esophageal, and skin toxicities were similar, although statistically not significant. Grade III haematological toxicity was less in the study arm.

Source link: https://doi.org/10.36106/ijsr/6407522


Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study

Abstract Purpose of this retrospective review The purpose of this retrospective study was to compare the effectiveness and safety of the atezolizumab plus carboplatin and nab-paclitaxel therapy with the carboplatin and nab-paclitaxel regimen with the carboplatin and nab-paclitaxel regimens with non-small cell lung cancer treatment in a select population. Methods & Criticism Patients with chronic, metastatic nonsquamous PD-L1-positive NSCLC who first received the atezolizumab plus carboplatin and nab-paclitaxel regimen, or carboplatin and nab-paclitaxel regimen were retrospectively identified in two medical centers from 2017 to 2020. These AEs were more prevalent in the ACN company than in the CN group, but they were manageable. Conclusions: Atezolizumab, combined with carboplatin and nab-paclitaxel chemotherapy may have increased anticancer activity among selected populations of patients with treatment-nave, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab, with a tolerable safety record, could lead to increased anticancer therapy in those populations of patients with treatment-nave, metastatic nonsquamous pactu.

Source link: https://doi.org/10.1007/s00432-021-03873-3


A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

Abstract Background In the absence of a targeted oncogenic driver mutation or high-programmed death-ligand 1 expression, systemic therapy with platinum-based doublet chemotherapy with or without bevacizumab has been the gold standard treatment for advanced or metastatic non-small cell lung cancer. On Arm B, the total survival of patients treated on Arm A was 15. 9 months and 13. 9 months. This is the first study to show a significant increase in PFS with the use of metformin in this patient population, according to the authors, and it is a sign of metformin's efficacy in advanced NSCLC. This is the first trial in nondiabetic advanced non-small cell lung cancer patients with the addition of metformin to standard first-line chemotherapy, according to the authors.

Source link: https://doi.org/10.1634/theoncologist.2017-0465


Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer

Lessons Learned In this phase II trial in non-small cell lung cancer, there is a lack of effectiveness associated with anti-EGFL7 therapy, as well as standard bevacizumab and chemotherapy, raising the challenge of increasing the effectiveness of VEGF inhibition in unselected populations. The efficacy of the anti-EGFL7 antibody parsatuzumab, as a component of bevacizumab plus platinum-based therapy for acute or recurrent nonsquamous non-small cell lung cancer is determined in this phase II trial. Patients were randomly assigned to placebo or parsatuzumab in combination with bevacizumab and carboplatin/paclitaxel, first and foremost, respectively, on day 1 of each 21-day cycle. The median PFS for the parsatuzumab arm was 6. 7 months compared to 8. 1 months for the placebo arm. For first-line NS-NSCLC, there was no evidence of effectiveness for parsatuzumab in the combination of bevacizumab and chemotherapy.

Source link: https://doi.org/10.1634/theoncologist.2017-0690


Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer

The median overall survival rate of 58 patients who were admitted to 14 hospitals in Japan was 66. 1%, in the group of 58 patients. Background Reporting The new survival results for a phase I/III trial of carboplatin plus nab-paclitaxel and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer were published here. Patients received weekly nab-paclitaxel at 50 mg/m2 for 6 weeks along with weekly carboplatin at an area under the curve of 2 mg/ml/min, as well as concurrent radiotherapy with 60 Gy in 30 fractions. The median PFS rate was 11. 8 months, and the 2-year PFS rate was 35. 9%. There were no differences in median PFS or OS, according to tumor histology or patient age. Conclusion Concurrent chemoradiation with nab-P/C was safe and provided a long-term survival benefit to patients with locally developed NSCLC.

Source link: https://doi.org/10.1634/theoncologist.2019-0746


Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer

Abstract Lessons Learned The biweekly GEM plus CBDCA dosage and schedule showed satisfactory results in elderly patients with elevated NSCLC with mild toxicities. The biweekly GEM plus CBDCA treatment may be regarded as an alternative to the 3-week NSCLC regimen. Background The gemcitabine-carboplatin combination is widely used for non-small cell lung cancer and has some benefit in elderly patients, but a high risk of thrombocytopenia has been identified, and the correct dosage and administration schedules are uncertain. This multicenter phase II trial examined the safety and tolerability of GEM-CBDCA for elderly patients with chemotherapy-associated NSCLC. Patients with chemotherapy-naive performance status 0–1 and stage IIIB/IV NSCLC were treated with chemotherapy biweekly, according to the author's instructions. In 76 years, the median age was 76 years; 35 percent were women; 35 patients were men; and 27 patients were diagnosed with adenocarcinoma. Conclusion This GEM-CBDCA combination administered biweekly demonstrated satisfactory results with mild toxicities in elderly patients with advanced NSCLC.

Source link: https://doi.org/10.1634/theoncologist.2019-0717


A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial

Serum Hsp27 levels were measured at baseline and during therapy. Arm A was 6. 0 and 10. 8 months, respectively, and Arm B was 4. 9 and 11. 8 months for Arm B, with Arm A being 6. 0 and 10. 8 months for Arm A. At baseline, sixteen patients had elevated serum Hsp27 at baseline, with 27 percent for Arm A and 32% for Arm B. Patients receiving apatorsen had median PFS of 10. 8 months, while placebo recipients had median PFS of 4. 8 months. Conclusion The addition of apatorsen to carboplatin and pewoxed was well tolerated, but in patients with metastatic nonsquamous NSCLC cancer in the first-line setting, there were no improvements. In the first-line setting, the addition of apatorsen to carboplatin and pemoglubular NSCLC cancer was well tolerated, but it did not improve outcomes in patients with metastatic nonsquamous NSCLC cancer.

Source link: https://doi.org/10.1634/theoncologist.2018-0518


Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301

Abstract Lessons Learned Each week, nanoparticle-bound paclitaxel in elderly patients with previously untreated, advanced non-small cell lung cancer demonstrated promising results, with less neuropathic toxicity in elderly patients with previously untreated, advanced non-small cell lung cancer. a subgroup analysis of elderly patients indicated that the CA031 trial demonstrated that weekly nanoparticle-bound paclitaxel was more effective in efficacy to paclitaxel every 3 weeks when combined with carboplatin for advanced non-small cell lung cancer patients; a subgroup analysis of elderly patients was encouraging. We prospectively evaluated the safety and tolerability of a modified CBDCA plus weekly nab-PTX for elderly patients with untreated advanced NSCLC in a multicenter phase II trial. Methods Eligible patients were treated with CBDCA on day 1 and nab-PTX, 8, and 15, respectively, every four weeks, according to the NHS. Conclusion Modified CBDCA Plus Weekly Nab-PTX demonstrated significant safety and tolerance in elderly patients with advanced NSCLC.

Source link: https://doi.org/10.1634/theoncologist.2017-0059


Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer

Abstract Lessons Learned This research, which looked at the effectiveness and safety of a carboplatin plus paclitaxel regimen in a biweekly or weekly schedule rather than the more costly 3-weekly regime, revealed that the weekly regimen was more effective than the biweekly regimen, which had mild toxicities in patients with non-small cell lung cancer patients. The weekly carboplatin plus paclitaxel regimen may be regarded as an alternative to the 3-weekly regimen in Japanese patients with NSCLC. BACKGROUNDER is the most commonly used treatment for advanced non-small cell lung cancer treated by combination therapy consisting of carboplatin and paclitaxel. We conducted a scientific trial to determine the correct chemotherapy regimen for Asian patients in the present study. The weekly CP regimen was sufficient to be considered an alternative to the existing 3-weekly regimen for NSCLC therapy.

Source link: https://doi.org/10.1634/theoncologist.2019-0513

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions